Patents Assigned to BioNumerik Pharmaceuticals, Inc.
-
Patent number: 6040312Abstract: This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an effective amount of the protective agent to a patient receiving one or more antineoplastic agents. The compounds useful as protective agents have either a sulfhydryl moiety or are reducible disulfides.Type: GrantFiled: January 5, 1999Date of Patent: March 21, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Thomas J. Dodd
-
Patent number: 6040294Abstract: This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an effective amount of the protective agent to a patient receiving one or more antineoplastic agents. The compounds useful as protective agents have either a sulfhydryl moiety or are reducible disulfides.Type: GrantFiled: January 6, 1999Date of Patent: March 21, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Thomas J. Dodd
-
Patent number: 6040330Abstract: A pharmaceutical formulation of a taxane antineoplastic agent, particularly paclitaxel or docetaxel or a pharmaceutically acceptable salt thereof, and N-methylpyrrolidin-2-one (NMP). The formulation may include other excipients and/or diluents, and is suitable for administration to patients with cancer.Type: GrantFiled: January 8, 1999Date of Patent: March 21, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Fredrick H. Hausheer, Dhanabalan Murali, Peddaiahgari Seetharamulu
-
Patent number: 6037336Abstract: To reduce the toxic effect of carboplatin, particularly myelosuppression and emesis, a dithioether having the formula R.sub.1 -(CH.sub.2).sub.n --S--S--(CH.sub.2).sub.m --R.sub.2 (I) wherein:each of R.sub.1 and R.sub.2 individually is SO.sub.3 H or PO.sub.3 H.sub.2 ; andeach of m and n is individually 1, 2, 3 or 4;or a pharmaceutically acceptable salt thereof, preferably disodium 2,2'-dithiobis(ethane sulfonate) (dimesna), is administered in combination with carboplatin to a patient, at substantially the same time or sequentially, whereby the dithioether and the carboplatin become co-present in the blood of the patient. Compositions comprising carboplatin and the dithioether are included in the invention.Type: GrantFiled: May 10, 1999Date of Patent: March 14, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Seetharamulu Peddaiahgari, Dasharatha G. Reddy
-
Patent number: 6034126Abstract: This invention relates to a method of treating patients afflicted with glycol poisoning. The method includes administering to a patient in need of treatment an antidotal amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.Type: GrantFiled: May 24, 1999Date of Patent: March 7, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick Herman Hausheer
-
Patent number: 6031006Abstract: This invention relates to a method of treating patients afflicted with diabetic nephropathy. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.Type: GrantFiled: October 21, 1999Date of Patent: February 29, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Aulma Parker, Seetharamulu Peddaiaghari
-
Patent number: 6028078Abstract: Novel compounds, formulations and methods of treating patients with cancer are provided for in this invention. The compounds are derivatives of camptothecin, and specifically relate to compounds having novel substitutions at the C-7 position of the camptothecin scaffold B-ring. The formula I compounds are highly lipophilic, lactone stable, do not require metabolic activation, and are potent antineoplastic compounds.Type: GrantFiled: October 26, 1998Date of Patent: February 22, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Pavankumar N. V. Petluru, Dasharatha Reddy, Dhanabalan Murali, Kochat Haridas, Peddaiahgari Seetharamulu, Shijie Yao
-
Patent number: 6025488Abstract: This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an effective amount of the protective agent to a patient receiving one or more antineoplastic agents. The compounds useful as protective agents have either a sulfhydryl moiety or are reducible disulfides.Type: GrantFiled: April 21, 1999Date of Patent: February 15, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick H. Hausheer
-
Patent number: 5998479Abstract: This invention relates to a method of treating patients afflicted with Adult Respiratory Distress Syndrome (ARDS). The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.Type: GrantFiled: February 9, 1999Date of Patent: December 7, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick Herman Hausheer
-
Patent number: 5958937Abstract: A- and/or B-ring substituted camptothecin derivatives, which are poorly water soluble (less than 5 micrograms per milliliter of water), are highly lipophilic camptothecin derivatives (HLCD) and are very active against a variety of human cancers. Because of their very poor water solubility, HLCD have not been used to treat human patients with cancer due to the inability to administer sufficient quantities of the HLCD dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable HLCD formulations for the direct administration of HLCD to human patients with cancer. The claimed invention also describes the methods to create solutions of HLCD and antitumor compositions of HLCD to allow the administration of HLCD in sufficient amounts to treat human patients with various types of cancer.Type: GrantFiled: October 22, 1997Date of Patent: September 28, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy
-
Patent number: 5955467Abstract: A- and/or B-ring substituted camptothecin derivatives, which are poorly water soluble (less than 5 micrograms per milliliter of water), are highly lipophilic camptothecin derivatives (HLCD) and are very active against a variety of human cancers. Because of their very poor water solubility, HLCD have not been used to treat human patients with cancer due to the inability to administer sufficient quantities of the HLCD dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable HLCD formulations for the direct administration of HLCD to human patients with cancer. The claimed invention also describes the methods to create solutions of HLCD and antitumor compositions of HLCD to allow the administration of HLCD in sufficient amounts to treat human patients with various types of cancer.Type: GrantFiled: October 22, 1997Date of Patent: September 21, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy
-
Patent number: 5935967Abstract: Pharmaceutical formulations of highly lipophilic, poorly water soluble derivatives of Camptothecin are disclosed. The formulations include an effective amount of the HLCD dissolved or suspended in an appropriate amount of N-methyl-2-pyrrolidinone (NMP), and one or more pharmaceutically acceptable excipients.Type: GrantFiled: January 20, 1998Date of Patent: August 10, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy
-
Patent number: 5922714Abstract: A method of treating patients with cancer which includes administering to a patient in need of such treatment an effective amount of a combination of .gamma.-methylene-10-deazaaminopterin, and either a 5-fluoropyrimidine or S-1.Type: GrantFiled: December 23, 1997Date of Patent: July 13, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick H. Hausheer
-
Patent number: 5922902Abstract: A process for synthesizing disulfides and sulfhydryl compounds which are useful pharmaceuticals. The process includes a two step, single pot process for preparing disulfides from an alkenyl sulfonate salt. The disulfides are useful as toxicity mitigating agents of chemotherapeutic drugs, such as certain platinum complexes, and as use therapeutic drugs for a variety of conditions in mammals.The two step process involves first the conversion of the starting reagent to a mercaptane sulfonate, then an oxidation to the desired disulfide.Type: GrantFiled: June 30, 1998Date of Patent: July 13, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Kochat Haridas
-
Patent number: 5919816Abstract: This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an effective amount of the protective agent to a patient receiving one or more antineoplastic agents. The compounds useful as protective agents have either a sulfhydryl moiety or are reducible disulfides.Type: GrantFiled: October 17, 1997Date of Patent: July 6, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Thomas J. Dodd
-
Patent number: 5910491Abstract: Novel compounds, formulations and methods of treating patients with cancer are provided for in this invention. The compounds are derivatives of camptothecin, and specifically relate to compounds having novel substitutions at the C-7 position of the camptothecin scaffold B-ring. The formula I compounds are highly lipophilic, lactone stable, do not require metabolic activation, and are potent antineoplastic compounds.Type: GrantFiled: August 19, 1997Date of Patent: June 8, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Pavankumar N.V. Petluru, Dasharatha Reddy, Dhanabalan Murali, Kochat Haridas, Peddaiahgari Seetharamulu, Shijie Yao
-
Patent number: 5902610Abstract: This invention describes novel formulations containing a water soluble disulfide, 2,2'-dithio-bis-ethane sulfonate, with or without cis-diammine dichloro platinum present in the same formulation, wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate is used to reduce the risk or prevent or retard the development of cisplatin induced nephrotoxicity, myelosuppression, and neurotoxicity, and wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate potentiates the antitumor activity of cisplatin when treating human patients with cancer. This invention also teaches novel formulations containing 2,2'-dithio-bis-ethane sulfonate alone or in combination with cisplatin in lyophilized or dissolved in an aqueous formulations which can be administered to patients with cancer who are being treated with cisplatin.Type: GrantFiled: November 3, 1995Date of Patent: May 11, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick Herman Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy, Seetharamulu Peddaiahgari
-
Patent number: 5900419Abstract: A- and/or B-ring substituted camptothecin derivatives, which are poorly water soluble (less than 5 micrograms per milliliter of water), are highly lipophilic camptothecin derivatives (HLCD) and are very active against a variety of human cancers. Because of their very poor water solubility, HLCD have not been used to treat human patients with cancer due to the inability to administer sufficient quantities of the HLCD dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable HLCD formulations for the direct administration of HLCD to human patients with cancer. The claimed invention also describes the methods to create solutions of HLCD and antitumor compositions of HLCD to allow the administration of HLCD in sufficient amounts to treat human patients with various types of cancer.Type: GrantFiled: October 22, 1997Date of Patent: May 4, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy
-
Patent number: 5880133Abstract: Pharmaceutical formulations of Highly Lipophilic Camptothecin Derivatives (HLCD) include HLCD dissolved in N-methyl Pyrrolidinene (NMP). The formulations also include quantities of pharmaceutically acceptable excipients and diluents incorporated thereinto.Type: GrantFiled: June 21, 1996Date of Patent: March 9, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy
-
Patent number: 5866169Abstract: This invention describes novel formulations containing a water soluble disulfide, 2,2'-dithio-bis-ethane sulfonate, with or without cis-diammine dichloro platinum present in the same formulation, wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate is used to reduce the risk or prevent or retard the development of cisplatin induced nephrotoxicity, myelosuppression, and neurotoxicity, and wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate potentiates the antitumor activity of cisplatin when treating human patients with cancer. This invention also teaches novel formulations containing 2,2'-dithio-bis-ethane sulfonate alone or in combination with cisplatin in lyophilized or dissolved in an aqueous formulations which can be administered to patients with cancer who are being treated with cisplatin.Type: GrantFiled: June 18, 1997Date of Patent: February 2, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick Herman Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy, Seetharamulu Peddaiahgari